Bernhard Gentner
Tumor immunology, Tumor microenvironment


Doctorate at German Cancer Research Center (DKFZ) and University of Heidelberg, 1998-2004

M.D. training at University of Heidelberg Medical School, Germany; MD Anderson Cancer Center and Baylor College of Medicine, Houston, Texas, 1996-2003.

Residency, Department of Internal Medicine, University of Erlangen, Germany, 2003-2006

Postdoctoral studies at Telethon Institute for Gene Therapy, Milano, Italy, 2006-2009

Residency, Hematology and Bone Marrow Transplant Unit, San Raffaele Hospital, Milano, Italy, 2009-2014

My group applies methods of advanced genetic engineering of hematopoietic stem cells to develop novel adoptive cell therapies against cancer and maintains a parallel program of clinical development that maximizes the exchange between laboratory and bedside in the development of such therapies. We leverage strategies to target transgene expression to tumor-infiltrating myeloid cells and are collaborating with our Hi-TIDe colleagues, particularly the T cell systems engineering group and tumor microenvironment & biomarker discovery group, to use this platform to deploy therapeutic payloads within the tumor microenvironment that synergize with adoptive T cell therapies.


Ludwig Institute for Cancer Research, Lausanne
Agora Research Center
Rue du Bugnon 25A, CH-1005 Lausanne

T (41) 21 545 10 77
F (41) 21 692 59 95


You are now leaving Ludwig Cancer Research's website and are going to a website that is not operated by the association. We are not responsible for the content or availability of linked sites. Do you wish to continue?